View clinical trials related to Metapneumovirus Infection.
Filter by:The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older. Treatment: - RSV/hMPV mRNA / LNP 1 at 3-4 different doses or, - RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or, - RSV mRNA / LNP 1 at 1 dose or, - hMPV mRNA / LNP 1 at 1 dose
This study evaluates a single use point of care diagnostic test in the diagnosis of influenza and other respiratory viral infections in adults. Participants will have a sample taken from their nose using a swab. The swab will be gently mixed in a liquid solution which will then be transferred into the device for testing.